Abstract:Topoisomerase has been found extremely high level of expression in hepatocellular carcinoma (HCC) and proven to promote the proliferation and survival of HCC. Cancer-associated fibroblasts (CAFs) as a kind of key reactive stromal cell that abundantly present in the microenvironment of HCC, could enhance the metastatic ability and drug resistance of HCC. Therefore, developing new drugs that address the above conundrums would be of the upmost significant in the fight against HCC. Evodiamine, as a multi-target natural product, has been found to exert various biological activities such as anti-cancer and anti-hepatic fibrosis via blocking topoisomerase, NF-kappa B, TGF-beta/HGF, and Smad2/3. Inspired by these facts, 15 evodiamine derivatives were designed and synthesized for HCC treatment by simultaneously targeting Topo I and CAFs. Most of them displayed preferable anti-HCC activities on three HCC cell lines and low cytotoxicity on one normal hepatic cell. In particular, compound 8 showed the best inhibitory effect on HCC cell lines and a good inhibition on Topo I in vitro. Meanwhile, it also induced obvious G(2)/M arrest and apoptosis, and significantly decreased the migration and invasion capacity of HCC cells. In addition, compound 8 down-regulated the expression of type I collagen in the activated HSC-T6 cells, and induced the apoptosis of activated HSC-T6 cells. In vivo studies demonstrated that compound 8 markedly decreased the volume and weight of tumor (TGI = 40.53%). In vitro and in vivo studies showed that its effects were superior to those of evodiamine. This preliminary attempt may provide a promising strategy for developing anti-HCC lead compounds taking effect through simultaneous inhibition on Topo I and CAFs.

Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy

Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity

Design, Synthesis, and Structure-Activity Relationships of Evodiamine-Based Topoisomerase (top)/histone Deacetylase (HDAC) Dual Inhibitors.

Indolo[3,2- c]isoquinoline Hydroxamic Acid Derivatives as Novel Orally Topoisomerase-Histone Deacetylase Dual Inhibitors for NSCLC Therapy

Identification of a novel 10-hydroxyevodiamine prodrug as a potent topoisomerase inhibitor with improved aqueous solubility for treatment of hepatocellular carcinoma

Synthesis , in vitro and in vivo antitumor activity and docking studies of new evodiamine derivatives

Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents.

Design, Synthesis and Bioactivity Evaluation of Novel N-phenyl-substituted Evodiamine Derivatives As Potent Anti-Tumor Agents

N(14)-substituted Evodiamine Derivatives As Dual Topoisomerase 1/Tubulin-Inhibiting Anti-Gastrointestinal Tumor Agents

Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.

Design, Synthesis and Anticancer Evaluation of Acridine Hydroxamic Acid Derivatives As Dual Topo and HDAC Inhibitors.

New Tricks for an Old Natural Product: Discovery of Highly Potent Evodiamine Derivatives As Novel Antitumor Agents by Systemic Structure-Activity Relationship Analysis and Biological Evaluations.

Water-soluble Derivatives of Evodiamine: Discovery of Evodiamine-10-phosphate As an Orally Active Antitumor Lead Compound.

The Discovery and Optimization of Novel Dual Inhibitors of Topoisomerase Ii and Histone Deacetylase

Design, Synthesis and Bioactivity Study of Evodiamine Derivatives As Multifunctional Agents for the Treatment of Hepatocellular Carcinoma.

Design, synthesis and biological evaluation of 2-amino-N-(2-aminophenyl)thiazole-5-carboxamide derivatives as novel Bcr-Abl and histone deacetylase dual inhibitors

Evodiamine, a Dual Catalytic Inhibitor of Type I and II Topoisomerases, Exhibits Enhanced Inhibition Against Camptothecin Resistant Cells.

Structure-activity Relationship Study of Novel Evodiamine Amino Acid Conjugates with Potent Anti-Colorectal Cancer Efficacy

Discovery of Epigenetic Modulators Targeting Hdacs and Ezh2 Simultaneously for the Treatment of Hematological Malignancies

Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors As a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.

Design, synthesis and bioactivity evaluation of favorable evodiamine derivative scaffold for developing cancer therapy